Statin use and risk of gastroduodenal ulcer and reflux esophagitis

Hepato-Gastroenterology

Volumn 56, Issue 91-92, 2009, Pages 641-644

  Fujii, Takaaki ^a,b   Nakabayashi, Toshihiro ^a,b   Hashimoto, Shinji ^a,b   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Gunma Pref Cardiovascular Center   (Japan)

Author keywords

Peptic ulcer; Reflux esophagitis; Statin

Indexed keywords

ATROVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GASTRODUODENAL ULCER; GASTROINTESTINAL ENDOSCOPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RISK FACTOR;

AGE FACTORS; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; ESOPHAGITIS, PEPTIC; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PEPTIC ULCER; RISK FACTORS;

EID: 67651233536     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Gaw A: A new reality: achieving cholesterol-lowering goals in clinical practice. Atherosclerosis 2002; 2:S5-S8.
2. Stein E: The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment. Atherosclerosis 2002; 2:S19-S23.
3. Davignon J: Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109:III39-III43.
4. Schonbeck U, Libby P: Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as antiinflammatory agents? Circulation 2004; 109:II18-II26.
5. Wolfrum S, Jensen KS, Liao JK: Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23:729-736.
6. Sparrow CP, Burton CA, Hernandex M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, Peterson L, Detmers PA, Chao YS, Wright SD: Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21:115-121. (Pubitemid 32061935)
7. Birnbaum Y, Ye Y, Rosanio S, Tavackoli S, Hu ZY, Schwarz ER, Uretsky BF: Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 2005; 65:345-355. (Pubitemid 40082476)
8. Douketis JD, Melo M, Bell CM, Mamdani MM: Does statin therapy decrease the risk for bleeding in patients who are receiving warfarin? Am J Med 2007; 120:e9-369.e14.
9. Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, Birnbaum Y: Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolsis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. Am Heart J 2006; 151:976.e1-6
10. Laufs U, La Fata V, Plutxky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998; 97:1129-1135. (Pubitemid 28152885)
11. Hirsch DP, Holloway RH, Tytgat GN, Boeckxstaens GE: Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology 1998; 115:1374-1380. (Pubitemid 28545987)
12. Konturek JW, Thor P, Lukaszyk A, Gabryelewicz A, Konturek SJ, Domschke W: Endogenous nitric oxide in the control of esophageal motility in humans. J Physiol Pharmacol 1997; 48:201-209. (Pubitemid 27305520)
13. Kassim SK, EI Touny M, EI Guinaidy M, EI Moghni MA, EI Mohsen AA: Serum nitrates and vasoactive intestinal peptide in patients with gastroesophageal reflux disease. Clin Biochem 2002; 35:641-646. (Pubitemid 36009332)
14. Hirch DP, Tiel-Van Buul MM, Tytgat GN, Boeckxstaens GE: Effect of L-NMMA on postprandial transient lower esophageal sphincter relaxations in healthy volunteers. Dig Dis Sci 2000; 45:2069-2075. (Pubitemid 30844697)
15. J Dent, J Brun, AM Fendrick, MB Fennerty, J Janssens, PJ Kahrilas, K Lauritsen, JC Reynolds, M Shaw, NJ Talley on behalf of the Genval Workshop Group: An evidence-based appraisal of reflux disease management -the Genval Workshop Report. Gut 1999; 44(Suppl 2):S1-S16.
16. Yuan Y, Padol IT, Hunt RH: Peptic ulcer disease today. Nat Clin Pract Gastroenterol Hepatol 2006; 3:80-89.
17. Chan FK, Leung WK: Peptic-ulcer disease. Lancet 2002; 360:933-941.
18. Huang JQ, Sridhar S, Hunt RH: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359:14-22. (Pubitemid 34119190)
19. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340:1888-1899. (Pubitemid 29272670)
20. Mittal RK, Lange RC, McCallum RW: Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia. Gastroenterology 1987; 92:130-135. (Pubitemid 17207671)
21. Sloan S, Kahrilas PJ: Impairment of esophageal emptying with hiatal hernia. Gastroenterology 1991; 100:596-605.
22. Tariq M, Khan HA, Elfaki I, Arshaduddin M, Al Moutaery M, AL Rayes H, AI Swailam R: Gastric antisecretory and antiulcer effects of simvastatin in rats. J Gastroenterol Hepatol 2007; 22:2316-2323. (Pubitemid 350145636)
23. Hagiwara M, Kataoka K, Arimochi H, Kuwahara T, Nakayama H, Ohnishi Y: Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal anti-inflammatory drug. World J Gastroenterol 2005; 11:1040-1043. (Pubitemid 40347760)
24. EI-Hajj II, Mourad FH, Shabb NS, Barada KA: Atrovastatin-induced severe gastric ulceration: a case report. World J Gastroenterol 2005; 11:3159-3160. (Pubitemid 40790683)
25. Hirsch DP, Tytgat GN, Boeckxstaens GE: Transient lower oesophageal sphincter relaxations - a pharmacological target for gastro-oesophageal reflux desease? Aliment Pharmacol Ther 2002; 16:17-26.
26. Vinjirayer E, Gonzalez B, Brensinger C, Bracy N, Obelmejias R, Katzka DA, Metz DC: Ineffective motility is not a marker for gastroesophageal reflux disease. Am J Gastroenterol 2003; 98:771-776. (Pubitemid 36576300)
27. Hayashi Y, Iwakiri K, Kotoyori M, Sakamoto C: Mechanisms of acid gastroesophageal reflux in the Japanese population. Dis Dis Si 2007; 53:1-6.
28. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME: Pravastatin limitation of atherosclerosis in the coronary arteries (PLACI): reduction in atherosclerosis progression and clinical events. PLACI investigation. J Am Coll Cardiol 1995; 26:1133-1139.
29. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events trial investigators. N Engl J Med 1996; 335:1001-1009.